VerImmune

About

VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection.

Baltimore,Maryland,United States
1 - 10
https://www.verimmune.com/

Highlights

Details

Last Funding Type: Seed
Last Funding Money Raised: $2.50M
Industries: Biotechnology,Health Care,Therapeutics
Founded date: Jan 1, 2020
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: VerImmune, Inc.

Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

$3.35M

VerImmune has raised a total of $3.35M in funding over 2 rounds. Their latest funding was raised on Jul 27, 2022 from a Seed round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jul 27, 2022	Seed	$2.50M	7	SeedFolio	—	Detail
May 6, 2020	Grant	$855.84K	1	National Science Foundation	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

8

VerImmune is funded by 8 investors. SeedFolio and National Science Foundation are the most recent investors.

Investor Name	Lead Investor	Funding Round
SeedFolio	Yes	Seed
National Science Foundation	Yes	Grant
Gaingels	—	Seed
Mana Ventures	—	Seed
Prox Ventures	—	Seed
Proxima Ventures Ltd	—	Seed
Tech Coast Angels San Diego	—	Seed
Ulu Ventures	—	Seed